A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects

被引：0

作者：

Gul, Ahmet ^{[1
]}

Ulker, Sibel ^{[2
]}

Senturk, Recep Selim ^{[2
]}

Turk, Ugur Onsel ^{[2
]}

Gurgun, Cemil ^{[2
]}

Lavrovsky, Yan ^{[3
]}

Samsonov, Mikhail ^{[4
]}

Ozen, Sebnem ^{[5
]}

Altinel, Serdar ^{[6
]}

机构：

[1] Istanbul Univ, Istanbul Fac Med, Div Rheumatol, Dept Internal Med, Istanbul, Turkey

[2] Ege Univ, Drug Dev & Pharmacokinet Res & Applicat Ctr ARGEF, Izmir, Turkey

[3] R Pharm Overseas Inc, San Diego, CA USA

[4] R Pharm JSC, Med Dept, Moscow, Russia

[5] TRPHARM Ilac AS, Clin Trial Dept, Istanbul, Turkey

[6] TRPHARM Ilac S, lin Trial Dept, Istanbul, Turkey

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1163

引用

页数：3

共 50 条

[1] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
Ahmadi, Ali R.
Atiee, George
Chapman, Bart
Reynolds, Laurie
Sun, John
Cameron, Andrew M.
Wesson, Russell N.
Burdick, James F.
Sun, Zhaoli
[J]. CELL REPORTS MEDICINE, 2023, 4 (09)
[2] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
[J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (10) : 945 - 954
[3] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Tadao Akizawa
Ryutaro Shimazaki
Masanari Shiramoto
Masafumi Fukagawa
[J]. Clinical Drug Investigation, 2018, 38 : 945 - 954
[4] Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Nuggehally R. Srinivas
[J]. Clinical Drug Investigation, 2019, 39 : 105 - 107
[5] Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Srinivas, Nuggehally R.
[J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (01) : 105 - 107
[6] Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
Tadao Akizawa
Ryutaro Shimazaki
Masanari Shiramoto
Masafumi Fukagawa
[J]. Clinical Drug Investigation, 2019, 39 : 109 - 111
[7] Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study"
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
[J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (01) : 109 - 111
[8] Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study
Oh, Jaeseong
Huh, Ki Young
Cho, Young-Gyu
Cha, Ji-Eun
Kim, Se-Jin
Yoon, Seo Hyun
Park, Sung Sup
Yoon, Hyunyee
Lee, Jieon
Lee, Howard
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (02) : 372 - 379
[9] Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects
Geven, Christopher
van Lier, Dirk
Blet, Alice
Peelen, Roel
ten Elzen, Bas
Mebazaa, Alexandre
Kox, Matthijs
Pickkers, Peter
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (09) : 2129 - 2141
[10] A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects
Han, Mai
Huo, Bishan
Hu, Gaoyun
Zhang, Xin
Cui, Gang
Wu, Wei
Mi, Na
Zhang, Shixi
Jin, Jiangli
Lu, Xing
Wu, Bidong
Xiao, Chunyan
Wang, Jing
Bian, Zheng
Li, Jintong
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15

← 1 2 3 4 5 →